| AFC-HD AMS Life Science Co. Ltd. (2927.TO) | ||
| Japan | ||
| Year Ended August 31 | ||
| GROUP | 2024 | 2023 |
| Revenue | Y30.19 bln | Y25.58 bln |
| Operating Profit | Y1.92 bln | Y1.64 bln |
| Pretax Profit | Y1.92 bln | Y1.65 bln |
| Net Profit | Y1.24 bln | Y1.10 bln |
| Per share | ||
| Earnings | Y88.64 | Y78.51 |
| Diluted Earnings | Y88.54 | Y78.46 |
| Results are based on Japanese accounting standards. |
This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.
(MORE TO FOLLOW) Dow Jones Newswires
October 15, 2024 02:00 ET (06:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.